Presenilins and apoptosis in transgenic models of alzheimer's disease

Informazioni relative al progetto

APOPTOSE PRESENILIN

ID dell’accordo di sovvenzione: QLK6-CT-1999-50727

Progetto chiuso

Data di avvio 23 Marzo 2001

Data di completamento 22 Marzo 2005

Finanziato da

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Costo totale € 96 000,00

Contributo UE € 96 000,00

Coordinato da

AVENTIS PHARMA S.A.
France

Obiettivo

Characterization of the signalling cascade involved in the increased sensitivity to apoptosis in primary culture of mutant presently transgenic mice.

Campo scientifico

• medical and health sciences › basic medicine › neurology › dementia › alzheimer

Programma(i)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Argomento(i)

• 1.1.1.-6. - Key action The Ageing Population and Disabilities

Invito a presentare proposte

Data not available

Meccanismo di finanziamento

BUR - Bursaries, grants, fellowships

Coordinatore

AVENTIS PHARMA S.A.

• Contributo UE: Nessun dato
• Indirizzo: Quai Jules Guesde, 13 ; 94403 VITRY SUR SEINE ; Francia
• Costo totale: Nessun dato